

Big Pharma Firm Gets Slap on the Wrist for Medicaid Fraud

By Mark Karlin

Global Research, August 29, 2017

Region: <u>USA</u>

Theme: <u>Law and Justice</u>, <u>Police State & Civil Rights</u>, <u>Poverty & Social Inequality</u>,

Science and Medicine

Featured image: The story of EpiPen pricing reveals why drug costs should be controlled. (Source: <u>Greg Friese</u>)

You may remember the EpiPen scandal — the massive price increases on the life-saving drug delivery system that saves people temporarily from allergic reactions — from awhile back. In 2016, The Daily Take Team wrote on Truthout,

Dozens of reports are now coming out about how Mylan Pharmaceuticals hiked the price of the very common life-saving EpiPen by over 450 percent since Mylan bought EpiPen in 2007.

You've probably heard of EpiPens, and you probably know someone who needs to carry two around with them at all times, just in case they have a severe allergic reaction as a result of some everyday occurrence — for example, encountering a food product with peanuts or being stung by a bee....

Read complete article here.

This article was originally published by <u>BuzzFlash / Truthout</u>.

Copyright, Truthout. Reprinted with <u>permission</u>.

The original source of this article is Global Research Copyright © Mark Karlin, Global Research, 2017

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Mark Karlin

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are

acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca